Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Article Dermatology

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data

Amy S. Paller et al.

Summary: The study findings indicate that dupilumab treatment in children and adolescents with AD does not increase overall infection risk and is associated with lower rates of skin infections compared to placebo.

PEDIATRIC DERMATOLOGY (2022)

Add to Collection

Letter Allergy

IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro

Pernille M. Hansen et al.

ALLERGY (2022)

Add to Collection

Review Dermatology

Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis

El-Bdaoui Haddad et al.

Summary: Type 2 immunity is an immune response evolved to combat helminth infections by orchestrating a combined protective response of innate and adaptive immune cells, promoting parasite destruction or expulsion, wound repair, and barrier function. Aberrant type 2 immune responses are associated with chronic tissue inflammation in allergic conditions, such as atopic dermatitis and asthma. Key cytokines of type 2 immunity include IL-4, IL-5, IL-9, IL-13, and IL-31, as well as IL-25, IL-33, and thymic stromal lymphopoietin. These cytokines play important roles in regulating inflammation, barrier function, and sensory nerve sensitization. Various therapeutic strategies targeting type 2 pathways have emerged to suppress type 2 inflammation.

DERMATOLOGY AND THERAPY (2022)

Add to Collection

Article Dermatology

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

A. S. Paller et al.

Summary: The study evaluated the pharmacokinetics, safety, and efficacy of single-dose dupilumab in children with severe AD aged 6 months to 6 years. The results showed generally good tolerability and substantial reduction in clinical signs/symptoms of AD, with slightly better responses in older children.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Dermatology

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma

Ashish Bansal et al.

Summary: This study evaluated the incidence and severity of conjunctivitis in adolescents receiving dupilumab treatment for moderate-to-severe atopic dermatitis or uncontrolled asthma. Results showed higher incidence of conjunctivitis in adolescents with atopic dermatitis treated with dupilumab compared to placebo, while lower rates were observed in asthma trials with both dupilumab and placebo.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Allergy

Atopic dermatitis in the pediatric population A cross-sectional, international epidemiologic study

Jonathan Silverberg et al.

Summary: This global survey in 18 countries revealed that atopic dermatitis affects a substantial proportion of the pediatric population, with less than 15% having severe cases. Prevalence and severity varied across countries and age groups, with rural areas generally having lower prevalence than urban or suburban areas.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Elaine C. Siegfried et al.

Summary: Laboratory testing is typically required for patients with atopic dermatitis (AD) treated with systemic immunosuppressants. However, in adolescents with moderate-to-severe AD treated with dupilumab, no clinically significant changes in laboratory parameters were observed, indicating no routine laboratory monitoring is needed.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020

Sylvia A. Martinez-Cabriales et al.

Summary: Dupilumab is currently the only biologic therapy approved in Europe and the United States for severe atopic dermatitis in patients aged 6 and above, with off-label use debated in younger children. Decision-making regarding vaccination for children on dupilumab is complex, dependent on various factors, highlighting the need for further research on the impact of dupilumab on immune responses to vaccines.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Allergy

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Jennifer D. Hamilton et al.

Summary: Dupilumab can effectively suppress type 2 inflammatory biomarkers in specific diseases and its impact on blood eosinophil responses varies by disease.

CLINICAL AND EXPERIMENTAL ALLERGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis

Mohamed A. Kamal et al.

Summary: The study demonstrated the efficacy and safety of Dupilumab for treating atopic dermatitis in adolescents and children. Based on pharmacokinetic profiles and exposure-response relationships, weight-tiered dosing regimens were proposed for adolescents and children in different weight categories.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Pediatrics

Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

Amy S. Paller et al.

Summary: This study assessed laboratory outcomes in children aged 6-11 years with severe atopic dermatitis treated with dupilumab. The results showed no clinically meaningful adverse changes in routine laboratory parameters, indicating that routine laboratory monitoring may not be necessary for this age group when treated with dupilumab for severe AD.

PEDIATRIC DRUGS (2021)

Add to Collection

Article Dermatology